Cardiovascular and Venous Thromboembolic Risk With JAK Inhibitors in Immune-Mediated Inflammatory Skin Diseases
JAMA Dermatology · 01.01.2024 · 160 (1) · 28
DOI: 10.1001/jamadermatol.2023.4090 ↗Kurz gefasst
Metaanalyse in der Zeitschrift JAMA Dermatology, erschienen am 01.01.2024. Verfasst von Jenne P Ingrassia und 6 weiteren Autor:innen. Beteiligte Einrichtung: Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, NYU Langone Health, New York. Hauptthemen laut MEDLINE: Janus Kinase Inhibitors, Venous Thromboembolism, Arthritis, Rheumatoid, Dermatitis, Atopic. Die Arbeit wurde bisher 100-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Janus kinase (JAK) inhibitors are an effective treatment option for patients with certain skin-related conditions, such as atopic dermatitis, alopecia areata, and vitiligo, but there is a current US Food and Drug Administration (FDA) boxed warning label for oral and topical JAK inhibitors regarding increased risk of major adverse cardiovascular events (MACE), venous thromboembolism (VTE), serious infections, malignant neoplasm, and death. However, this boxed warning was precipitated by results of the Oral Rheumatoid Arthritis Trial (ORAL) Surveillance study, which only included patients with rheumatoid arthritis, and the same association may not be observed in dermatologic conditions.
Objective
To determine the risk of all-cause mortality, MACE, and VTE with JAK inhibitors in patients with dermatologic conditions. Data Sources PubMed and ClinicalTrials.gov were searched from database inception to April 1, 2023. Study Selection This review included phase 3 randomized clinical trials with a placebo/active comparator group of JAK inhibitors used for a dermatologic indication with FDA approval or pending approval or with European Union or Japanese approval. Studies without a comparison group, case reports, observational studies, and review articles were excluded. Data Extraction and Synthesis This study was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. Adverse events using odds ratios (ORs) and 95% CIs were calculated using a random-effects model and the DerSimonian-Laird method. Studies were screened, data abstracted, and quality assessed by 2 independent authors. The protocol was prospectively registered with PROSPERO. Main Outcomes and Measures Primary outcomes were a composite of adjudicated MACE and all-cause mortality, and VTE.
Results
The analysis included 35 randomized clinical trials with 20 651 patients (mean [SD] age, 38.5 [10.1] years; male, 54%) and a mean (SD) follow-up time of 4.9 (2.68) months. Findings did not show a significant difference between JAK inhibitors and placebo/active comparator in composite MACE and all-cause mortality (OR, 0.83; 95% CI, 0.44-1.57) or VTE (OR, 0.52; 95% CI, 0.26-1.04). Conclusions and Relevance In this systematic review and meta-analysis, use of JAK inhibitors was not associated with increased risk of all-cause mortality, MACE, and VTE compared to the placebo/active comparator groups. Additional trials with long-term follow-up are needed to better understand the safety risks of JAK inhibitors used for dermatologic indications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, NYU Langone Health, New York.
- New York Medical College, Valhalla, New York.
- DeBakey Heart and Vascular Center, Department of Cardiology, Methodist Hospital, Houston, Texas.
- University of Pennsylvania Perelman School of Medicine, Philadelphia.
- Brigham and Women's Hospital, Boston, Massachusetts.
- Leon H. Charney Division of Cardiology, New York University Grossman School of Medicine, New York.
Zitieren
APA
Ingrassia, J. P., Maqsood, M. H., Gelfand, J. M., Weber, B. N., Bangalore, S., Lo Sicco, K. I., & Garshick, M. S. (2024). Cardiovascular and Venous Thromboembolic Risk With JAK Inhibitors in Immune-Mediated Inflammatory Skin Diseases. JAMA Dermatology, 160(1), 28. https://doi.org/10.1001/jamadermatol.2023.4090
Vancouver
Ingrassia JP, Maqsood MH, Gelfand JM, Weber BN, Bangalore S, Lo Sicco KI, et al. Cardiovascular and Venous Thromboembolic Risk With JAK Inhibitors in Immune-Mediated Inflammatory Skin Diseases. JAMA Dermatology. 2024;160(1):28. doi:10.1001/jamadermatol.2023.4090
BibTeX
@article{Ingrassia2024,
author = {Ingrassia, Jenne P and Maqsood, Muhammad Haisum and Gelfand, Joel M and Weber, Brittany N and Bangalore, Sripal and Lo Sicco, Kristen I and Garshick, Michael S},
title = {Cardiovascular and Venous Thromboembolic Risk With JAK Inhibitors in Immune-Mediated Inflammatory Skin Diseases},
journal = {JAMA Dermatology},
year = {2024},
volume = {160},
number = {1},
pages = {28},
doi = {10.1001/jamadermatol.2023.4090}
}
EUVIMED